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Edited by Felix WielandAbstract Mucolipin-1 is a 65-kDa membrane protein encoded
by the MCOLN1 gene, which is mutated in patients with
mucolipidosis type IV (MLIV), a rare neurodegenerative lyso-
somal storage disorder. We studied the subcellular localization
of wild-type and three diﬀerent mutant forms (T232P, F408del
and F465L) of mucolipin by expressing Myc-tagged proteins in
HeLa cells. The overexpressed wild-type mucolipin colocalizes to
late endocytic structures and induces an aberrant distribution of
these compartments. F408del and F465L MLIV mutant proteins
show a distribution similar to the wild-type protein, whereas
T232P is retained in the endoplasmic reticulum. Among the
mutants, only F408del induces a redistribution of the late
endocytic compartment. These ﬁndings suggest that the overex-
pression of the mucolipin cation channel inﬂuences the dynamic
equilibrium of late endocytic compartments.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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endosome1. Introduction
First described in 1974 [1], mucolipidosis type IV (MLIV,
MIM 252650) is an autosomal recessive lysosomal storage
disorder. To date approximately 100 patients have been re-
ported all over the world, the majority of whom are of Ash-
kenazi Jewish (AJ) descent [2,3]. The frequency in the AJ
population has recently been estimated to be 1/40 000, with
heterozygote frequency of 1/100 [4,5]. The disease presents it-
self during the ﬁrst years of life and patients show little dete-
rioration for the ﬁrst three decades [6], with life expectancy and
prognosis beyond the third decade still unknown. Clinically,
MLIV is characterized by profound psychomotor retardation,
ophthalmologic abnormalities including corneal opacity, reti-* Corresponding author. Fax: +39-030-3701157.
E-mail address: gborsani@med.unibs.it (G. Borsani).
Abbreviations: MLIV, mucolipidosis type IV; MCOLN1, mucolipin-1
gene; MLN1, mucolipin-1 protein; MLN2, mucolipin 2 protein;
MLN3, mucolipin 3 protein; AJ, Ashkenazi Jews; TRP, transient
receptor potential; PC2, polycystin-2
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gastrin levels. This last ﬁnding is apparently caused by con-
stitutive achlorhydria and provides a simple biochemical
marker to assist in diagnosis [2]. Considerable heterogeneity in
the clinical symptoms and severity of the disease has been re-
ported even among siblings. At the cellular level, sphingolipids,
phospholipids and acid mucopolysaccharides accumulate in
the lysosomes from every tissue and organ of MLIV patients as
single-membrane bound granular inclusions and lamellar
concentric bodies [1,6,8–13]. The lysosomal storage results
from an abnormal sorting and/or transport along the late
endocytic pathway [6,8], while the lysosomal hydrolases in-
volved in the catabolism of the stored products have normal
activity and the stored materials are normally catabolized. The
loss of balance between transport of components into lyso-
somes and their catabolism [8,14] oﬀers an explanation for the
heterogeneous nature of the stored molecules and the absence
of organomegaly or skeletal deformations seen in many other
lysosomal storage diseases [6]. MLIV is caused by mutations in
MCOLN1, a gene mapping to 19p13.3 [15–17]. Two founder
MCOLN1 mutations were identiﬁed to comprise 95% of the
mutant alleles among Ashkenazi MLIV families in correlations
with two haplotypes [18]. The major AJ mutation, present on
the 72% of the AJ MLIV alleles, is an A–G transition at the 30
acceptor site of intron 3. The minor mutation is a 6432-bp
genomic deletion spanning a region from the 50 end of the gene
to the ﬁrst 12 bp of exon 7 and is found in the 23% of the AJ
MLIV alleles. MCOLN1 encodes a 580-amino acid protein
with a predicted molecular weight of 65 kDa that has been
named mucolipin-1 (MLN1). Structural analysis of the amino
acid sequence predicts that the protein has six transmembrane
(TM) domains, with both the N- and C-termini residing in the
cytoplasm (Cyt), and a putative di-leucine motif (L–L–X–X)
located at the C-terminus as a late endosomal–lysosomal-tar-
geting motif (Fig. 1A). MLN1 shows 49% amino acid identity
to MLN2 and 57.2% to MLN3 [19], two yet uncharacterized
polypeptides belonging to the same transient receptor potential
(TRP) family [20]. Mucolipin has indeed been recently dem-
onstrated to represent a novel Ca2þ-permeable channel tran-
siently modulated by changes in Ca2þ concentration whose
function is inhibited by reduction of pH [21,22]. It also has
signiﬁcant structural similarity to polycystin-2 (PC2), another
6 TM Ca2þ-permeant channel, which is mutated in some casesblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic illustration of the putative structure of mucolipin and
Western blot analysis of wild-type and mutant mucolipin. (A) Mucol-
ipin has six predicted transmembrane domains (1–6), with the N- and
C-termini in the cytoplasm (Cyt). The approximate position of the
mutations analyzed is shown. They are two missense mutations (T232P
and F465L) and a single codon deletion (F408del). Mutations described
in patients with a severe phenotype are underlined. Ext, external; Cyt,
cytoplasmic; L, lysosomal targeting signal (L–L–X–X). (B) HeLa cells
were transfected with wild-type, T232P, F465L and F408del Myc-tag-
ged mucolipins or control vector (pMT21). Cells were harvested 24 h
after transfection and subjected to SDS–8 M urea PAGE, followed by
immunoblot analysis with rabbit anti-Myc antibody. The overexpres-
sed protein isoforms are indicated at the top of each lane. Arrows in-
dicate the position of the mucolipin monomer and putative dimer. No
signal is detectable in the mock (pMT21) transfected lane.
220 M. Manzoni et al. / FEBS Letters 567 (2004) 219–224of autosomal dominant polycystic kidney disease [15–17,20].
Interestingly, PC2 is involved in basolateral traﬃcking of
proteins and lipids in polarized cells.
This study represents the ﬁrst comparative analysis of the
cellular distribution of wild-type and mutant mucolipin forms.2. Materials and methods
2.1. Expression constructs
Mucolipin-Myc construct. Primers MYML129E (50-AGGAATT-
CATGACAGCCCCGGCGGGTC-30) and MY129S (50-AAGTC-
GACAATTCACCAGCAGCGAATG-30) were used to amplify the
entire MCOLN1 ORF by PCR using cloned Pfu polymerase (Strata-
gene) and 2517653 IMAGE cDNA clone as template. The PCR
product was digested with EcoRI and SalI and was cloned into the
pMT21 expression vector (which contains a CMV promoter and a
SV40 polyadenylation signal) to generate an open reading frame
encoding mucolipin with a COOH-terminal Myc-tag (mucolipin-
Myc construct).
Mucolipin-HA construct. ML129BGL (50-ATAGATCTATG-
ACAGCCCCGGCGGGTC-30) and 129/ECO (50-GGAATTCT-
CAATTCACCAGCAGCGAATG-30) primers containing suitable
restriction sites were used to amplify and clone the MCOLN1 coding
region in pMHA vector. Mucolipin-hemagglutinin (HA) contains the
ampliﬁed insert 50 in-frame with the HA epitope within plasmid pMHA.
The pMHA vector contains a CMV promoter and a SV40 polyadenyl-
ation signal.
All mutant mucolipin constructs (F408del-, T232P- and F465L-
mucolipin) [5,16,17] were generated using the QuikChange Site-Di-
rected Mutagenesis Kit (Stratagene) following the manufacturer’s
protocol and the mucolipin-Myc construct previously described.
Mutations were conﬁrmed by automated ﬂuorescent sequencing.
The ORF encoding each mucolipin mutant is 30 in-frame with the
Myc epitope into the plasmid pMT21.
2.2. Cell culture and transient transfections
Human cervical cancer cell line HeLa and African green monkey
kidney cells Cos7 were maintained in Dulbecco’s modiﬁed Eagle’s
medium (Euroclone Life Sciences), supplemented with 5% (v/v) fetal
bovine serum (HyClone), 100 U/ml penicillin, 100 lg/ml streptomycinand 2 mM L-glutamine (Gibco, Invitrogen Life Technologies) at 37 C
in a 5% CO2 humidiﬁed incubator. For immunoﬂuorescence studies,
HeLa and Cos7 cells were seeded on sterile glass coverslips (BDH) in
six-wells plates (Corning Life Sciences) or in 60-mm culture dishes
(Corning Life Sciences). Transfections were carried out using FuGene
6 (Roche) according to the manufacturer’s guidelines. Brieﬂy, cells
were incubated with DNA/FuGene 6 reagent mixture (ratio DNA/
Fugene¼ 1/3) in serum-free medium (Optimem, Invitrogen Life
Technologies) for 5 h, followed by culturing in 5% FBS-containing
medium. Mock transfectants were obtained with the same amount of
pMT21 or pHA expression vector. Cells were either collected for
protein analysis or ﬁxed for immunoﬂuorescence at diﬀerent times
after transfection.
2.3. Protein extraction and immunoblot analyses
HeLa cells were transfected with Myc-tagged mucolipin or one of
the Myc-tagged mucolipin mutants for 24 h; 10 lg of the cell lysate
were subjected to 8 M urea–SDS–10% (w/v) polyacrylamide gel elec-
trophoresis and subsequently transferred by electroblotting onto Im-
mobilon-P blotting membrane (Amersham Biosciences). The
membrane was incubated for 30 min in PBS containing 0.1% (v/v)
Tween 20 and 5% (w/v) dried milk (blocking buﬀer) and subsequently
incubated with rabbit anti-Myc antibody (Sigma) followed by incu-
bation with horseradish peroxidase-conjugated anti-rabbit immuno-
globulins (Amersham Biosciences). Proteins were visualized using
enhanced chemiluminescence immunoblotting detection reagent
(Amersham Biosciences).
2.4. Lysosomal enzyme assays
Control and transfected HeLa cells were cultured for 12 h in the
presence or absence of 5 mM mannose 6-phosphate sodium salt (Sig-
ma) to inhibit receptor-mediated endocytosis of secreted lysosomal
hydrolases. Lysosomal enzyme activities including b-hexosaminidase
and b-galactosidase were determined both in cell extracts and culture
media by using appropriate colorimetric substrates by commonly used
methods [23]. The assay was carried out in two separate experiments,
each point in triplicate.
2.5. Immunoﬂuorescence and microscopy
Transfected cells grown on coverslips were rinsed with PBS, imme-
diately ﬁxed with 3% (w/v) PBS-buﬀered paraformaldehyde for 15 min,
washed in PBS, quenched in 50 mM NH4Cl for 10 min and permea-
bilized in PBS containing 0.5% saponin. Cells were subsequently im-
munolabeled using an indirect procedure in which all incubations
(primary, secondary antibodies and washes) were performed in solu-
tion containing 0.5% saponin.
Primary antibodies used were: rabbit anti-Myc antibody (Sigma),
mouse anti-Myc (Sigma), mouse anti-LAMP1 (BD Biosciences),
mouse anti-early endosome antigen 1 (EEA1) (BD Biosciences
Pharmingen), rabbit anti-calnexin (Stressgen), mouse anti-GM130 (BD
Biosciences Pharmingen), anti-cytochrome c (Promega) and rabbit
anti-catalase (Calbiochem). Anti-lysobisphosphatidic acid (LBPA) and
anti-46-kDa mannose 6-phosphate receptor (MPR46) were generously
provided by J. Gruenberg (University of Geneve) and S. Hoening
(University of Gottingen), respectively. For lysosomes labeling,
Lysotracker Red (Molecular Probes) was used. After 24 h transfection,
cells were incubated with 100 nM Lysotracker for 30 min following the
manufacturer’s instructions. Staining was obtained after incubation
with Cy2- and/or Cy3-conjugated isotype-speciﬁc antibodies (Jackson
ImmunoResearch Laboratories). Controls included staining with each
secondary antibody separately. Coverslips were then washed in PBS,
mounted on a glass microscopic slide (BDH) with Fluorescent
Mounting Medium (Dako) and examined using a confocal microscope
(MRC-1024 BioRad).
Images were processed with Image ProPlus (Media Cybernetics,
Silver Spring, MD) and Adobe Photoshop software. For quantitation
of overlap between mucolipin (wild-type and mutants) and LAMP1
computer-assisted image quantiﬁcation with the Image ProPlus soft-
ware was used. Brieﬂy, binary images for both markers to be compared
were combined using a logical and, so as to yield an image of only
those pixels which were positive in both images. The total number of
pixels in each of the binary images and the combined image were
compared to give the percentage of colocalization [24]. Values given
represent the mean from ﬁve separate cells, in at least two diﬀerent
experiments.
Fig. 2. Confocal microscopy analysis of the intracellular distribution of
wild-type mucolipin and colocalization with LAMP1. HeLa cells were
transiently transfected with wild-type mucolipin-Myc construct. 24 h
after transfection, cells were stained with rabbit anti-Myc, mouse anti-
LAMP1 antibodies and subsequently Cy2- and Cy3-conjugated
secondary antibodies. (A) Intracellular distribution of wild-type
mucolipin. (B) Endogenous LAMP1 subcellular distribution. Cells
overexpressing mucolipin, indicated by asterisk, show an altered dis-
tribution of LAMP1-positive compartments. (C) Colocalization be-
tween wild-type mucolipin and LAMP1. (D) Higher magniﬁcation of
the inset in C. Computer-assisted image quantiﬁcation indicates that
about 52% of mucolipin colocalizes with LAMP1-positive compart-
ments (see white arrows). In addition, blue arrows show mucolipin-
positive structures that do not completely colocalize with LAMP1.
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3.1. Generation and expression of wild-type and mutant
mucolipin constructs
To get more insight into the molecular mechanism and the
function of mucolipin, we localized the wild-type protein in
cultured mammalian cells and analyzed whether mutations in
mucolipin aﬀect proper stability and subcellular distribution of
the protein. A schematic illustration of the putative structure
of mucolipin together with the position of the mutations
studied is shown in Fig. 1A. The in-frame deletion F408del and
the missense mutation F465L are within the transient receptor
potential (TRP) domain of the protein [17], located near the
intracellular border of the fourth transmembrane domain and
in the pore-forming loop, respectively. The position of these
mutated residues suggests an alteration of the channel func-
tionality. A mutation in the same region of the protein has
been recently described (V446L) that does not impair mucol-
ipin channel activity but aﬀects its inhibition by reduction of
pH [22]. Conversely, the T232P mutation, located in the ﬁrst
putative extracellular loop outside the TRP domain [25], is
probably not directly involved in channel activity.
Due to the lack of antibodies that allow the detection of the
endogenous mucolipin, the expression and intracellular local-
ization of the wild-type and mutant mucolipin isoforms were
studied by epitope-tagged protein transient expression.
We ﬁrst constructed Myc- and HA-tagged wild-type mu-
colipin and three Myc-tagged mucolipin mutants. The T232P-,
F465L-, F408del-mucolipin mutations were generated indi-
vidually in MCOLN1 cDNA by PCR-mediated site-directed
mutagenesis. We subsequently transfected HeLa cells with the
diﬀerent Myc-tagged mucolipin constructs.
The expression of wild-type mucolipin and of mucolipin
mutant proteins was conﬁrmed by Western blot analysis. We
were not able to separate mucolipin as a discrete protein band
using classical SDS–PAGE under reducing conditions (data
not shown). On the contrary, using SDS–8 M urea PAGE,
wild-type and mutant mucolipin appear as a band of about 130
kDa (Fig. 1B). In addition, a minor band of approximately 65
kDa, corresponding to the calculated molecular weight of
tagged mucolipin, is detected by anti-Myc antibody. No sig-
niﬁcant degradation phenomena are observed, as demon-
strated by the absence of low molecular weight bands. Overall,
this electrophoretic behavior suggests that mucolipin tends to
form aggregates and/or to interact with other proteins to create
complexes characterized by strong intra-molecular interac-
tions. This hypothesis is supported by the ﬁnding that TRP
channels are composed by polypeptide subunits that assemble
as multimers to form cation permeable pores [20,26]. The
composition of these mucolipin complexes is one of the issues
that might be clariﬁed to better understand the biochemical
and functional characteristics of this integral membrane
protein.
3.2. Subcellular localization of wild-type mucolipin
Subcellular localization experiments were initially carried
out using both Myc- and HA-tagged proteins (data not
shown). The Myc-tag construct was then routinely used be-
cause we obtained the brightest staining under our experi-
mental conditions. Wild-type Myc-tagged mucolipin has a
similar distribution both in HeLa and Cos7 cells (data not
shown) and localizes in punctuated structures dispersed in theCyt (Fig. 2A). To determine if the protein distribution varies
with expression time, we monitored the subcellular localization
of the Myc-tagged mucolipin in HeLa cells at 6, 9, 12, 24 and
48 h post-transfection and no signiﬁcant time-dependent
changes were observed (data not shown). To further charac-
terize the cellular structures containing mucolipin, we com-
pared its distribution to markers of diﬀerent cellular
compartments. Mucolipin failed to localize to either mito-
chondria, peroxisomes, the Golgi apparatus, or to the endo-
plasmic reticulum (data not shown). Mucolipin partially
colocalizes with the late endosomes/lysosomes marker LAMP1
(Fig. 2). This colocalization is in agreement with: (i) the
presence of a di-leucine motif (L–L–X–X) as a late endosomal–
lysosomal targeting signal located at the C-terminus of the
protein [17]; (ii) the lysosomal nature of the disease and (iii) the
analogous results obtained in Xenopus oocytes [21]. As shown
in Fig. 2, despite a 52% of colocalization, a subset of mucolipin
appears to be strictly adjacent to some LAMP1-positive vesi-
cles, but it does not exactly colocalize with them (see blue ar-
rows, Fig. 2D). These mucolipin-positive LAMP1-negative
structures are diﬃcult to identify unambiguously but may
reasonably represent traﬃcking intermediates in these ﬂuid
cellular compartments.
Interestingly, HeLa cells overexpressing mucolipin (indi-
cated with an asterisk in Fig. 2B) show an anomalous distri-
bution and morphology of the compartment identiﬁed by
LAMP1 compared to non-transfected cells. In particular,
lysosomes appear more dispersed within Cyt with respect to
222 M. Manzoni et al. / FEBS Letters 567 (2004) 219–224non-transfected cells. The meaning of this redistribution is not
yet understood and could be due to the overexpression of a
functional mucolipin cation channel, since we cannot observe
any similar redistribution of lysosomes in cells overexpressing
the mutant F465L and T232P forms (see below).
To further investigate this interesting phenomenon, addi-
tional markers for the endocytic pathway have been used.
These include a marker for the early endocytic compartment,
such as EEA1, and the more widely distributed MPR46, a
protein involved in the delivery of lysosomal enzymes [27]. No
evident colocalization with EEA1 was observed and no redis-
tribution of the early endocytic compartment was promoted by
the overexpression of mucolipin (data not shown). Conversely,
mucolipin is present, to a limited extent, in compartments la-
beled by MPR46 that might correspond to late endosomal
structures (Fig. 3A). It is not obvious whether the over-
expression of mucolipin promotes also a redistribution of
MPR46-positive structures.
For late endosomal–lysosomal compartment we used
Lysotracker, a ﬂuorescent acidotropic probe for labeling and
tracking acidic organelles, and LBPA, a marker of late endo-
somes. Similarly to what we observed for LAMP1, also
Lysotracker and LBPA-positive compartments appear to be
redistributed in mucolipin overexpressing cells (Figs. 3B and
C, respectively). The merge of the confocal images indicatesFig. 3. Confocal microscopy analysis of wild-type mucolipin and colocalizat
transiently transfected with mucolipin-Myc construct for 24 h and then sta
antibodies together with rabbit anti-Myc. Cells were subsequently stained w
mucolipin transfected cells. Mucolipin partially colocalizes with MPR46 (A), L
(C, middle row) are redistributed in mucolipin expressing cells (asterisks).that mucolipin colocalizes with Lysotracker and LBPA al-
though with a lower degree of colocalization compared with
the one observed for LAMP1. This may indicate that overex-
pressed mucolipin behaves like a dynamic protein that moves
through the late endocytic compartment in a way similar to
LAMP1. On the contrary, LBPA is a resident late endosomal
marker and Lysotracker is a unidirectional endocytic ﬂuid
phase marker that accumulates in mature lysosomes. The ly-
sosomal–late endosomal localization of mucolipin is consistent
with recent data on cup-5, a Caenorhabditis elegans functional
ortholog of MCOLN1. Mutations in cup-5 result in the ac-
cumulation of large vacuoles in several cells, in increased cell
death and in embryonic lethality [28,29]. CUP-5 protein lo-
calizes to nascent and mature lysosomes, in particular to
subdomains of the late endosomes where lysosomally destined
endocytic cargo accumulates in buds [30]. Taken together,
these data indicate that CUP-5 and human mucolipin are re-
quired for lysosome reformation/biogenesis.
The delivery of lysosomal enzymes from the Golgi to the
endosomal compartment is mediated by MPR46, while the
delivery from endosomes to lysosomes is MPR46-independent.
Although we did not observe a signiﬁcant redistribution of
MPR46 in mucolipin overexpressing cells, we cannot exclude
that the ﬁnal targeting of lysosomal enzymes is somehow im-
paired, considering the redistribution of the late endocyticion with diﬀerent markers for the endocytic pathway. HeLa cells were
ined alternatively with anti-MPR46, Lysotracker Red or anti-LBPA
ith Cy2- and Cy3-conjugated secondary antibodies. Asterisks indicate
ysotracker (B) and LBPA (C). Lysotracker (B, middle row) and LBPA
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point, we evaluated the enzymatic activities of two lysosomal
hydrolases (b-hexosaminidase and b-galactosidase) both in
cells and media from mucolipin transfected cells. In order to
inhibit receptor-mediated endocytosis of secreted lysosomal
enzymes, cells were grown both in the presence or absence of
mannose 6-phosphate. Under these experimental conditions,
no signiﬁcant diﬀerences were found neither in the media nor
in cell extracts of transfected and untransfected cells (data not
shown), indicating that the lysosomal sorting machinery does
not appear to be grossly aﬀected by mucolipin overexpression.
3.3. Subcellular localization of mucolipin mutants
We then analyzed the subcellular distribution of three pre-
viously described naturally occurring mutations located inFig. 4. Confocal microscopy analysis showing subcellular localization of tagg
with mucolipin mutants cDNAs (A–D) as indicated in the left row. Cells were
the respective cellular marker as indicated in the middle row. Merged images
the ER protein calnexin (A). F465L-mucolipin partially localizes (28%) to
degree of colocalization (37%) with LAMP1-positive compartment (C). Only
A higher magniﬁcation of the inset in C.distinct regions of the protein. The mutations studied were: a
single amino acid deletion (F408del) [16,17] and two missense
mutations, T232P and F465L [5] (Fig. 1A). Analysis of the
mutated amino acid residues demonstrates a variable amount
of sequence conservation amongst members of the mucolipin
family. The residues corresponding to F408 and F465 in hu-
man mucolipin are conserved in the mouse, Drosophila and C.
elegans [28,29] putative orthologs and in the MLN3 [19], while
the T232 residue appears to be conserved only in mouse
Mcoln1 [31].
The T232P mutant fails to localize to late endocytic com-
partments and clearly accumulates in the ER, as shown by its
restricted distribution to calnexin-positive structures (Fig. 4A).
As a possible explanation, the T232 residue might be somehow
involved in the proper transport of mucolipin through theed mutant forms of mucolipin. HeLa cells were transiently transfected
ﬁxed after 24 h of expression and stained with anti-Myc antibody and
are shown in the right row. The T232P mutant protein colocalizes with
LAMP1-positive vesicles (B). F408del mutant protein shows a higher
F408del mutant induces redistribution of LAMP1-positive vesicles. (D)
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result in the misfolding of the protein leading to a diverted
route of maturation and delivery by chaperons. Although the
functional role of the loop where this mutation occurs is still
unknown, it is interesting to note that mucolipin and PC2
(both involved in diseases characterized by an intracellular
traﬃcking defect) are the only members of the TRP super-
family having such a large extracellular loop between the ﬁrst
and the second transmembrane domains. Although these data
have been obtained by overexpression techniques, the com-
plete mislocalization of T232P mutant we observed is in
agreement with the severe clinical phenotype described in the
MLIV patient carrying this mutation [5].
Both F465L and F408del mutants show a punctuated cy-
toplasmic distribution similar to the wild-type protein. As
shown in Fig. 4B–D, the mucolipin mutant proteins are either
colocalizing or adjacent to LAMP1-positive compartments. To
date the precise nature of the LAMP1-negative structures
where the wild-type and F465L and F408del proteins distrib-
ute is not clear. A more detailed analysis performed using
computer-assisted image quantiﬁcation reveals that the degree
of colocalization with LAMP1 is higher for the F408del than
for the F465L protein (see also legend of Fig. 4). Interestingly,
only overexpression of F408del induces an altered distribution
of the late endosomal–lysosomal marker LAMP1, as already
observed for the wild-type protein.
The latter observation suggests that, despite a similar sub-
cellular localization of F465L and F408del mutants, only the
latter seems to maintain at least part of the capability of the
wild-type protein to promote a redistribution of the late end-
ocytic compartments when overexpressed. These ﬁndings are
supported by the clinical observations: these mutations have
been described in two patients who are both compound het-
erozygotes for the major AJ splice mutation [5]. The patient
carrying the in-frame deletion F408del is characterized by
unusual mild psychomotor retardation [32], while the patient
carrying F465L amino acid substitution mutation has a severe
clinical phenotype similar to those patients completely lacking
mucolipin protein.
Although our studies, based on protein overexpression,
cannot unambiguously establish the subcellular localization of
the endogenous wild-type and mutant mucolipin isoforms,
they provide precious hints about the importance of the cor-
rect gene dosage in MLIV therapeutic approaches based on
gene therapy.
Acknowledgements: This work was supported by the Italian Telethon
Grant GP0190 ‘‘Understanding the molecular basis of MLIV’’ to G.B.,
by the Fondazione Cariplo Grants ‘‘Omniexpress’’ and ‘‘RNA inter-
ference’’ to S.B. and G.B., and by the MURST Coﬁn 2002 to G.B. We
thank Prof. N. Manca (Universita’ di Brescia, Italy) for providing
access and support with confocal imaging equipment, M. Gennarelli,
C. Scassellati (I.R.C.C.S. ‘‘S. Giovanni di Dio’’, Fatebenefratelli,
Brescia, Italy) and M. Di Luca (Universita’ di Milano, Italy) for use of
the microscopy facilities, J. Gruenberg (University of Geneve, Swit-
zerland) for anti-LBPA antibody, S. Hoening (University of Gottigen,
Germany) for anti-MPR46 antibody, M.T. Pizzo (Telethon Institute ofGenetics and Medicine, Naples, Italy) for technical assistance and
G. Kargul for critical reading of the manuscript.References
[1] Berman, E.R., Livni, N., Shapira, E., Merin, S. and Levij, I.S.
(1974) J. Pediatr. 84, 519–526.
[2] Schiﬀmann, R. et al. (1998) Proc. Natl. Acad. Sci. USA 95, 1207–
1212.
[3] Raas-Rothschild, A., Bargal, R., DellaPergola, S., Zeigler, M. and
Bach, G. (1999) Eur. J. Hum. Genet. 7, 496–498.
[4] Bach, G. (2001) Mol. Genet. Metab. 73, 197–203.
[5] Bargal, R. et al. (2001) Hum. Mutat. 17, 397–402.
[6] Chen, C.-S., Bach, G. and Pagano, R.E. (1998) Proc. Natl. Acad.
Sci. USA 95, 6373–6378.
[7] Amir, N., Zlotogora, J. and Bach, G. (1987) Pediatrics 79, 953–
959.
[8] Bargal, R. and Bach, G. (1997) J. Inherit. Metab. Dis. 20, 625–
632.
[9] Goebel, H.H., Kohlschutter, A. and Lenard, H.G. (1982) Clin.
Neuropathol. 1, 73–82.
[10] Merin, S., Livni, N., Berman, E.R. and Yatziv, S. (1975) Invest.
Ophthalmol. 14, 437–448.
[11] Folkerth, R.D., Alroy, J., Lomakina, I., Skutelsky, E., Raghavan,
S.S. and Kolodny, E.H. (1995) J. Neuropathol. Exp. Neurol. 54,
154–164.
[12] Bargal, R. and Bach, G. (1988) J. Inherit. Metab. Dis. 11, 144–
150.
[13] Goldin, E., Blanchette-Mackie, E.J., Dwyer, N.K., Pentchev, P.G.
and Brady, R.O. (1995) Pediatr. Res. 37, 687–692.
[14] Bargal, R. and Bach, G. (1989) Clin. Chim. Acta 181, 167–174.
[15] Bassi, M.T., Manzoni, M., Monti, E., Pizzo, M.T., Ballabio, A.
and Borsani, G. (2000) Am. J. Hum. Genet. 67, 1110–1120.
[16] Bargal, R. et al. (2000) Nat. Genet. 26, 118–123.
[17] Sun, M. et al. (2000) Hum. Mol. Genet. 9, 2471–2478.
[18] Slaugenhaupt, S.A., Acierno, J.S.J., Helbling, L.A., Bove, C.,
Goldin, E., Bach, G., Schiﬀmann, R. and Gusella, J.F. (1999) Am.
J. Hum. Genet. 65, 773–778.
[19] Di Palma, F., Belyantseva, I.A., Kim, H.J., Vogt, T.F., Kachar, B.
and Noben-Trauth, K. (2002) Proc. Natl. Acad. Sci. USA 99,
14994–14999.
[20] Clapham, D.E. (2003) Nature 426, 517–524.
[21] LaPlante, J.M., Falardeau, J., Sun, M., Kanazirska, M., Brown,
E.M., Slaugenhaupt, S.A. and Vassilev, P.M. (2002) FEBS Lett.
532, 183–187.
[22] Raychowdhury, M.K. et al. (2004) Hum. Mol. Genet. 13, 617–
627.
[23] Yuen, C.T., Price, R.G., Chattagoon, L., Richardson, A.C. and
Praill, P.F. (1982) Clin. Chim. Acta 124, 195–204.
[24] Nichols, B.J., Kenworthy, A.K., Polishchuk, R.S., Lodge, R.,
Roberts, T.H., Hirschberg, K., Phair, R.D. and Lippincott-
Schwartz, J. (2001) J. Cell Biol. 153, 529–541.
[25] Slaugenhaupt, S.A. (2002) Curr. Mol. Med. 2, 445–450.
[26] Littleton, J.T. and Ganetzky, B. (2000) Neuron 26, 35–43.
[27] Ghosh, P., Dahms, N.M. and Kornfeld, S. (2003) Nat. Rev. Mol.
Cell. Biol. 4, 202–212.
[28] Fares, H. and Greenwald, I. (2001) Nat. Genet. 28, 64–68.
[29] Hersh, B.M., Hartwieg, E. and Horvitz, H.R. (2002) Proc. Natl.
Acad. Sci. USA 99, 4355–4360.
[30] Treusch, S., Knuth, S., Slaugenhaupt, S.A., Goldin, E., Grant,
B.D. and Fares, H. (2004) Proc. Natl. Acad. Sci. USA 101, 4483–
4488.
[31] Falardeau, J.L., Kennedy, J.C., Acierno Jr., J.S., Sun, M., Stahl,
S., Goldin, E. and Slaugenhaupt, S.A. (2002) BMC Genomics 3, 3.
[32] Reis, S., Sheﬀer, R.N., Merin, S., Luder, A.S. and Bach, G. (1993)
Am. J. Med. Genet. 47, 392–394.
